WO2009026282A3 - Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist - Google Patents

Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist Download PDF

Info

Publication number
WO2009026282A3
WO2009026282A3 PCT/US2008/073581 US2008073581W WO2009026282A3 WO 2009026282 A3 WO2009026282 A3 WO 2009026282A3 US 2008073581 W US2008073581 W US 2008073581W WO 2009026282 A3 WO2009026282 A3 WO 2009026282A3
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
treatment
receptor agonist
endothelin
compositions
Prior art date
Application number
PCT/US2008/073581
Other languages
French (fr)
Other versions
WO2009026282A2 (en
Inventor
Anil Gulati
Original Assignee
Midwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University filed Critical Midwestern University
Priority to US12/673,140 priority Critical patent/US8623823B2/en
Priority to CN2008801134256A priority patent/CN101888851B/en
Priority to EP08798175.9A priority patent/EP2182977B1/en
Priority to ES08798175.9T priority patent/ES2584509T3/en
Priority to JP2010521975A priority patent/JP5956715B2/en
Priority to CA2696398A priority patent/CA2696398C/en
Publication of WO2009026282A2 publication Critical patent/WO2009026282A2/en
Publication of WO2009026282A3 publication Critical patent/WO2009026282A3/en
Priority to US14/149,785 priority patent/US9493524B2/en
Priority to US15/352,238 priority patent/US10112981B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of using an ETB receptor agonist, such as IRL- 1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
PCT/US2008/073581 2007-08-21 2008-08-19 Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist WO2009026282A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/673,140 US8623823B2 (en) 2007-08-21 2008-08-19 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
CN2008801134256A CN101888851B (en) 2007-08-21 2008-08-19 Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist
EP08798175.9A EP2182977B1 (en) 2007-08-21 2008-08-19 Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist
ES08798175.9T ES2584509T3 (en) 2007-08-21 2008-08-19 Compositions for the treatment of stroke or stroke with an endothelin B receptor agonist
JP2010521975A JP5956715B2 (en) 2007-08-21 2008-08-19 Method for treating stroke or cerebrovascular disorder using an ETB receptor agonist
CA2696398A CA2696398C (en) 2007-08-21 2008-08-19 Methods for treatment of stroke or cerebrovascular accidents using an etb receptor agonist
US14/149,785 US9493524B2 (en) 2007-08-21 2014-01-07 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
US15/352,238 US10112981B2 (en) 2007-08-21 2016-11-15 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96559107P 2007-08-21 2007-08-21
US60/965,591 2007-08-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/673,140 A-371-Of-International US8623823B2 (en) 2007-08-21 2008-08-19 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
US14/149,785 Continuation US9493524B2 (en) 2007-08-21 2014-01-07 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist

Publications (2)

Publication Number Publication Date
WO2009026282A2 WO2009026282A2 (en) 2009-02-26
WO2009026282A3 true WO2009026282A3 (en) 2009-09-03

Family

ID=40378953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/073581 WO2009026282A2 (en) 2007-08-21 2008-08-19 Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist

Country Status (8)

Country Link
US (3) US8623823B2 (en)
EP (1) EP2182977B1 (en)
JP (2) JP5956715B2 (en)
CN (1) CN101888851B (en)
CA (1) CA2696398C (en)
ES (1) ES2584509T3 (en)
PL (1) PL2182977T4 (en)
WO (1) WO2009026282A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2334378T3 (en) 2008-08-19 2014-07-07 Xenoport Inc Methyl hydrogen fumarate prodrugs, pharmaceutical compositions thereof and methods of use
ES2614813T3 (en) 2009-04-30 2017-06-02 Midwestern University New therapeutic treatments using centaquine
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
CA3171883C (en) * 2013-07-08 2024-03-05 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
JP2016534133A (en) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド Crystal form of (N, N-diethylcarbamoyl) methyl methyl (2E) but-2-ene-1,4-dioate, its synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2024057296A2 (en) 2023-06-28 2024-03-21 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and a process for preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055470A (en) * 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
WO2004037235A2 (en) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors
US20070032422A1 (en) * 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIYAL S ET AL: "Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats.", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY MAY 2007, vol. 29, no. 4, May 2007 (2007-05-01), pages 257 - 263, XP008107899, ISSN: 0379-0355 *
CHUQUET JULIEN ET AL: "Selective blockade of endothelin-B receptors exacerbates ischemic brain damage in the rat.", STROKE, vol. 33, no. 12, December 2002 (2002-12-01), pages 3019 - 3025, XP002535071, ISSN: 0039-2499 *
ZUCCARELLO M ET AL: "Endothelin B receptor antagonists attenuate subarachnoid hemorrhage - Induced cerebral vasospasm", STROKE 199809 US, vol. 29, no. 9, September 1998 (1998-09-01), pages 1924 - 1929, XP002535070, ISSN: 0039-2499 *

Also Published As

Publication number Publication date
JP5956715B2 (en) 2016-07-27
PL2182977T3 (en) 2017-01-31
ES2584509T3 (en) 2016-09-28
US8623823B2 (en) 2014-01-07
EP2182977B1 (en) 2016-05-04
JP2014169310A (en) 2014-09-18
EP2182977A2 (en) 2010-05-12
CA2696398C (en) 2018-05-08
US10112981B2 (en) 2018-10-30
PL2182977T4 (en) 2017-01-31
CN101888851B (en) 2013-11-20
US20170298105A1 (en) 2017-10-19
WO2009026282A2 (en) 2009-02-26
JP2010536868A (en) 2010-12-02
US20140193393A1 (en) 2014-07-10
US9493524B2 (en) 2016-11-15
US20120093798A1 (en) 2012-04-19
CN101888851A (en) 2010-11-17
CA2696398A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2009026282A3 (en) Compositions for the treatment of stroke or cerebrovascular accidents with an endothelin b receptor agonist
WO2013023732A3 (en) Ternesite used as an activator for latent-hydraulic and pozzolanic materials
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
IL243710A (en) Substituted benzoazepines as toll-like receptor modulators, compositions comprising the same and uses thereof
EP2085419A4 (en) Process for producing modified polymer, modified polymer obtained by the process, and rubber composition containing the same
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
IL199680A0 (en) Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof
EP2345679A4 (en) Method for producing graft copolymer, graft copolymer obtained by the method, rubber composition containing the graft copolymer, and tire
EP2285900A4 (en) Gel composition, method for preparing the same, and impact resistant absorbing material using the same
IL218193A (en) Substituted benzoazepines as toll-like receptor modulators, compositions comprising the same and uses thereof
WO2007022351A3 (en) Muscarinic acetylcholine receptor antagonists
WO2009014855A3 (en) Ink formulations and methods of making ink formulations
EP2284204A4 (en) Copolymer, method for producing the same and water repellent oil repellent composition
BRPI0918487A2 (en) process for the preparation of a copolymer composition, composition, and use of a copolymer composition
WO2010003567A3 (en) Fluorosurfactants
BRPI0917728A2 (en) composition, use of the composition, and method of preventing foaming in a composition
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
BRPI0923291A2 (en) process for the distillation of an aqueous polymethylol mixture, composition, and use of a polymethylol.
WO2009152167A3 (en) Delivery of therapeutics
WO2010005622A3 (en) Telescoping devices
WO2008094942A3 (en) Humanized antibodies against cxcr3
WO2007047397A3 (en) Phenol ethers as modulators of the opioid receptors
WO2008121775A3 (en) Device for the delivery of viscous compositions
WO2009080351A9 (en) Compounds with anti-emetic effect
EP2208745A4 (en) Polymer compound, method for producing the same, and composition containing the polymer compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113425.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08798175

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2696398

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010521975

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008798175

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1603/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12673140

Country of ref document: US